GlobalRPh Medical News Roundup
Clinical developments for September 18-24, 2026
Each week, we review clinically important developments from the FDA, CDC, WHO, NIH, major peer-reviewed medical journals, and professional societies. Our objective is to provide physicians, pharmacists, nurses, advanced practice clinicians, and other healthcare professionals with a concise, evidence-based summary of developments that may influence clinical practice, medication management, diagnostic evaluation, patient counseling, or public health response.
This edition covers authoritative publications and material updates released from Friday, September 18, through Thursday, September 24, 2026. Regulatory actions, safety communications, randomized and observational evidence, systematic reviews, and expert consensus are distinguished below. Items are ordered by anticipated clinical importance.
Previous:
- August 3rd through the 9th.
- Top Medical News Topics Clinicians Should Know This Week: July 20-26, 2026
- July 6-12, 2026
- June 29th through July 5th 2026
- Top Medical News – Time window: June 15–21, 2026, inclusive
- The Changing Geography of Sexually Transmitted Infections in the United States.
- Estimated STI burden Calculator.
Topic summary
| # | Topic | Category | Source and date | Clinical takeaway |
|---|---|---|---|---|
| 1 | Belzutifan plus lenvatinib for clear-cell RCC | FDA regulatory action | FDA, Sep 24 | The combination improved progression-free survival after prior PD-1 or PD-L1 therapy, but not overall survival. |
| 2 | Lirafugratinib for FGFR2-altered cholangiocarcinoma | FDA regulatory action | FDA, Sep 23 | A new FGFR inhibitor produced a 46% response rate in previously treated, FGFR inhibitor-naive disease. |
| 3 | Imlunestrant plus abemaciclib for ESR1-mutated breast cancer | FDA regulatory action | FDA, Sep 18 | Blood-based ESR1 testing identifies patients eligible for this post-endocrine therapy combination. |
| 4 | Levacetylleucine for ataxia-telangiectasia | FDA regulatory action | FDA, Sep 18 | Aqneursa becomes the first FDA-approved treatment for ataxia associated with ataxia-telangiectasia. |
| 5 | INCA neonatal CPAP sets | FDA Class I recall update | FDA, Sep 18 | Affected sets should not be used because tubing may disconnect and cause loss of CPAP pressure. |
| 6 | Hepatitis A associated with Cuba travel | CDC surveillance evidence | CDC MMWR, Sep 24 | Pretravel hepatitis A prevention and post-travel diagnostic vigilance are warranted. |
| 7 | Medicare Advantage and kidney transplantation | Observational evidence | JAMA, Sep 21 | Medicare Advantage enrollment was associated with lower wait-listing and transplantation rates among patients with kidney failure. |
| 8 | Congenital TORCH infections and neurodevelopment | Observational evidence | JAMA Pediatrics, Sep 21 | Diagnosed congenital infection was associated with substantially higher intellectual disability and autism risks. |
| 9 | Transvaginal drainage for tubo-ovarian abscess | Randomized noninferiority evidence | JAMA Surgery, Sep 23 | Noninferiority to laparoscopy was not established, and reintervention was more frequent. |
| 10 | Anticoagulation intensity in hospitalized COVID-19 | Randomized evidence | JAMA Network Open, Sep 23 | Therapeutic anticoagulation did not significantly improve the primary outcome over prophylactic dosing. |
| 11 | Intravenous versus oral iron in pregnancy | Meta-analysis of randomized trials | JAMA Network Open, Sep 23 | IV iron improved hematologic outcomes and reduced transfusion, without showing better obstetric outcomes. |
| 12 | Probiotics in very preterm infants | Observational effectiveness evidence | JAMA Network Open, Sep 23 | Routine probiotic use was associated with lower necrotizing enterocolitis and mortality. |
| 13 | Short oral corticosteroid courses in type 2 diabetes | Observational safety signal | JAMA Network Open, Sep 23 | Brief corticosteroid exposure was followed by increased pneumonia, heart failure, and gastrointestinal bleeding. |
| 14 | Hypertensive disorders of pregnancy and dementia | Observational evidence | JAMA Network Open, Sep 24 | The apparent association with dementia was largely attenuated after accounting for later vascular and metabolic disease. |
| 15 | Personalized bacteriophage therapy | Consensus guideline | Nature Medicine, Sep 21 | New recommendations address quality-controlled selection, preparation, administration, and monitoring of personalized phage therapy. |
| 16 | Antidepressants and QTc prolongation | Network meta-analysis of randomized trials | BMJ, Sep 23 | Escitalopram and amitriptyline produced small average QTc increases, without a demonstrated short-term major cardiovascular event signal. |
| 17 | Gene therapy for Wiskott-Aldrich syndrome | Long-term nonrandomized evidence | NEJM, Sep 24 | Etuvetidigene autotemcel was associated with durable survival and fewer serious infections and bleeding events. |
| 18 | NHS-Galleri multi-cancer detection test | Secondary test-performance analysis | Nature Medicine, Sep 22 | Specificity and positive predictive value were high, but overall cancer sensitivity was limited and the parent trial missed its primary endpoint. |
| 19 | Undiagnosed CKD in heart failure | Secondary randomized-trial analysis | JAMA Cardiology, Sep 23 | Albuminuria testing identified substantial unrecognized CKD and higher-risk patients with HFmrEF or HFpEF. |
| 20 | Global health workforce aging | WHO workforce surveillance | WHO, Sep 18 | Nearly one-quarter of physicians are older than 55, adding retirement pressure to projected global workforce shortages. |
Clinical summaries
1. FDA approves belzutifan plus lenvatinib for previously treated clear-cell RCC
What changed: FDA approved belzutifan with lenvatinib for adults with advanced renal cell carcinoma containing a clear-cell component after prior PD-1 or PD-L1 inhibitor therapy.
Why it matters for clinicians: In the 747-patient randomized LITESPARK-011 trial, median progression-free survival was 14.6 months with the combination versus 10.6 months with cabozantinib, with a hazard ratio of 0.74. Objective response rates were 53% and 40%, respectively.
Practical clinical relevance: The regimen adds a post-immunotherapy option with a different mechanistic profile. Monitor for anemia, hypoxia, hypertension, cardiac dysfunction, proteinuria, renal and hepatic toxicity, thromboembolic events, QT prolongation, hemorrhage, wound-healing complications, and other labeled risks.
Caveats: Overall survival was not significantly improved: median survival was 33.7 versus 28.6 months, with a hazard ratio of 0.85. Treatment selection should consider prior VEGF therapy, comorbidities, toxicity burden, and alternative later-line regimens.
2. Lirafugratinib approved for previously treated FGFR2-altered cholangiocarcinoma
What changed: FDA approved once-daily lirafugratinib for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement.
Why it matters for clinicians: In the single-arm REFOCUS trial, 116 FGFR inhibitor-naive patients had an objective response rate of 46%. Median response duration was 11.8 months.
Practical clinical relevance: Comprehensive tumor genomic testing should be obtained early enough to guide later-line treatment. Patients require ophthalmologic assessment and monitoring for hyperphosphatemia, soft-tissue mineralization, and treatment-related ocular symptoms.
Caveats: Approval was based on response and durability in a nonrandomized population rather than comparative survival evidence. The trial does not establish efficacy after another FGFR inhibitor, and acquired resistance is expected to remain clinically important.
3. Imlunestrant plus abemaciclib approved for ESR1-mutated breast cancer
What changed: FDA approved imlunestrant with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer progressing after at least one endocrine regimen. Guardant360 CDx was approved as a companion blood-based test.
Why it matters for clinicians: In an exploratory 159-patient ESR1-mutated subgroup of EMBER-3, median progression-free survival was 11.1 months with the combination versus 5.5 months with imlunestrant alone. The hazard ratio was 0.53, and response rates were 35% versus 15%.
Practical clinical relevance: Circulating tumor DNA testing can identify endocrine resistance and treatment eligibility. Monitor for diarrhea, neutropenia, hepatotoxicity, venous thromboembolism, and interstitial lung disease or pneumonitis.
Caveats: The approval-relevant ESR1 analysis was exploratory, and overall survival remains immature. Benefit from imlunestrant monotherapy was not demonstrated in tumors without a detectable ESR1 mutation.
4. Levacetylleucine becomes the first approved ataxia treatment for ataxia-telangiectasia
What changed: FDA approved levacetylleucine oral suspension for adults and pediatric patients with ataxia-telangiectasia weighing at least 15 kg.
Why it matters for clinicians: In a 73-patient randomized, double-blind, two-period crossover trial, functional Scale for Assessment and Rating of Ataxia scores were better during levacetylleucine treatment than during placebo treatment.
Practical clinical relevance: Neurology and genetic-disease programs may consider treatment alongside rehabilitation, fall prevention, immune management, malignancy surveillance, and supportive care. Falls, skin lacerations, urinary tract infections, pregnancy risk, and drug interactions should be reviewed.
Caveats: Each treatment period lasted only 12 weeks. Durability, effects on long-term functional independence, and influence on non-neurologic manifestations of ataxia-telangiectasia remain uncertain.
5. FDA classifies INCA infant and neonatal CPAP recall as Class I
What changed: FDA updated its earlier communication to identify the CooperSurgical INCA Infant and Neonatal Nasal CPAP recall as Class I, its most serious recall category.
Why it matters for clinicians: A loose connection between the flexible tubing and nasal cannula can leak or disconnect, causing loss of CPAP pressure and reduced oxygenation in newborns or infants.
Practical clinical relevance: Facilities should identify affected lots, stop use and distribution, segregate the products, notify relevant clinical personnel, and return the sets to CooperSurgical. If disconnection occurs during use, respiratory support must be restored promptly with unaffected equipment.
Caveats: The underlying removal and customer notification began before this review period; the new development is FDA’s September 18 classification. No serious injuries or deaths had been reported as of August 11.
6. CDC details a hepatitis A outbreak associated with travel to Cuba
What changed: CDC reported that 76 of 249 hepatitis A cases identified in Florida from June 2024 through February 2026 involved recent travel to Cuba. Seventy-nine cases met the outbreak definition, 72% were hospitalized, and no deaths occurred.
Why it matters for clinicians: Fifteen of 18 genotyped isolates shared the same genotype IA strain, supporting widespread transmission associated with Cuba. Travel-related exposures continued to be reported during 2026.
Practical clinical relevance: Review hepatitis A immunization before travel. CDC advises considering immune globulin for adults older than 40 years, immunocompromised travelers, and people with chronic liver disease departing within two weeks. Consider hepatitis A in compatible illness after Cuba travel.
Caveats: Sequencing and detailed exposure questionnaires were available for only subsets of cases. Official surveillance data from Cuba were limited, and exposures could not always be assigned to a specific location or source.
7. Medicare Advantage enrollment is associated with reduced access to kidney transplantation
What changed: A retrospective cohort study of 630,848 adults with end-stage kidney disease compared transplant access under Medicare Advantage and traditional Medicare during 2021-2023.
Why it matters for clinicians: Medicare Advantage enrollment was associated with lower transplantation rates, 2.51 versus 4.60 per 1,000 person-months, and lower wait-listing rates. Adjusted rate ratios were 0.71 and 0.77, respectively.
Practical clinical relevance: Nephrology practices and transplant programs should refer patients early, document delays, help navigate plan networks and authorization requirements, and monitor whether insurance-related barriers impede evaluation or listing.
Caveats: This was observational evidence. Differences in patients, geography, plan selection, provider networks, and administrative processes could contribute to the association. The study does not prove that Medicare Advantage enrollment directly caused reduced transplantation.
8. Congenital TORCH infections are associated with adverse neurodevelopmental outcomes
What changed: A Swedish cohort of more than 3.6 million births identified 975 children with diagnosed congenital TORCH infections and evaluated subsequent neurologic, psychiatric, and academic outcomes.
Why it matters for clinicians: Congenital infection was associated with higher risks of intellectual disability and autism in population-level and sibling comparisons. The association was particularly strong for severe intellectual disability.
Practical clinical relevance: Prevention remains central, including rubella vaccination, syphilis screening and treatment, and counseling to reduce cytomegalovirus exposure. Diagnosed children warrant hearing, vision, growth, developmental, and neurologic follow-up tailored to the pathogen and clinical findings.
Caveats: Diagnosed cases likely overrepresented symptomatic infections. Surveillance bias, incomplete characterization of pathogen timing and severity, and the relatively small exposed group limit causal and pathogen-specific interpretation. The findings do not support indiscriminate universal TORCH panels.
9. Transvaginal drainage does not establish noninferiority to laparoscopy for tubo-ovarian abscess
What changed: A French randomized trial compared ultrasound-guided transvaginal drainage with laparoscopic treatment in 208 patients with tubo-ovarian abscess.
Why it matters for clinicians: In the per-protocol analysis, clinical cure occurred in 72.5% after transvaginal drainage and 77.0% after laparoscopy. The confidence interval crossed the prespecified noninferiority boundary, so noninferiority was not demonstrated.
Practical clinical relevance: Transvaginal drainage may shorten hospitalization and produce faster early pain improvement in appropriately selected patients with an accessible abscess and experienced operators. However, reintervention occurred more frequently, 13.0% versus 3.3%.
Caveats: Attrition reduced the per-protocol sample to 130 patients, limiting statistical precision. Results should not be generalized to unstable patients, suspected rupture, uncertain diagnosis, inaccessible abscesses, or circumstances requiring operative evaluation.
10. Therapeutic anticoagulation does not significantly improve outcomes in hospitalized COVID-19
What changed: A randomized trial of 139 hospitalized patients compared therapeutic-dose with prophylactic-dose anticoagulation.
Why it matters for clinicians: The 42-day composite of death, venous thromboembolism, or arterial thrombosis occurred in 21% versus 29%, respectively, with a hazard ratio of 0.74 and a nonsignificant P value of .40.
Practical clinical relevance: Anticoagulation intensity should follow current guidance and individualized assessment of thrombosis, illness severity, renal function, procedures, and bleeding risk. Therapeutic dosing remains indicated when a confirmed or otherwise established indication exists.
Caveats: The trial was small and underpowered to exclude clinically important benefit or harm. Major or clinically relevant bleeding occurred in seven therapeutic-dose recipients and four prophylactic-dose recipients. The findings do not support universal treatment-dose escalation.
11. IV iron improves hematologic outcomes during pregnancy but not obstetric outcomes
What changed: A systematic review and meta-analysis of 29 randomized trials involving approximately 11,800 participants compared intravenous with oral iron during pregnancy.
Why it matters for clinicians: IV iron improved maternal hematologic outcomes, increased neonatal ferritin, and was associated with fewer transfusions and fewer mild adverse effects. Gestational age, birth weight, and cesarean delivery did not significantly differ.
Practical clinical relevance: IV iron is particularly relevant for moderate or severe deficiency, oral iron intolerance, inadequate oral response, malabsorption, or later pregnancy when rapid repletion is needed. Product selection should consider formulation, dosing burden, infusion resources, and hypersensitivity protocols.
Caveats: Trials varied in iron formulations, doses, gestational timing, anemia definitions, and outcome reporting. Serious events and patient-centered clinical outcomes were uncommon or inconsistently reported. The evidence does not require replacing oral iron as first-line therapy for every patient.
12. Probiotic implementation is associated with lower NEC and mortality in very preterm infants
What changed: A Swedish cohort compared outcomes in 4,695 infants born at 28 to 31 weeks before and after probiotic implementation.
Why it matters for clinicians: Death or necrotizing enterocolitis occurred in 0.8% of probiotic-exposed infants and 3.4% of unexposed infants, with an adjusted risk ratio of 0.28. NEC and mortality were each lower when evaluated separately.
Practical clinical relevance: NICUs considering probiotic protocols should address strain selection, product quality, storage, preparation, eligibility, central-line precautions, and surveillance for probiotic-associated infection.
Caveats: This was not randomized. Guideline-era changes in feeding, infection prevention, or neonatal care could have contributed. Results are formulation-specific and should not be extrapolated automatically to extremely preterm infants, different products, or settings without pharmaceutical-grade quality assurance.
13. Corticosteroid bursts are followed by increased acute complications in type 2 diabetes
What changed: A Taiwanese self-controlled cohort evaluated 36,048 adults with type 2 diabetes who received short oral corticosteroid courses with a median duration of three days.
Why it matters for clinicians: During days 6-30 after exposure, incidence rate ratios were 2.06 for pneumonia, 1.87 for heart failure, and 1.71 for gastrointestinal bleeding. A smaller gastrointestinal bleeding signal and an increased fracture rate persisted during days 31-90.
Practical clinical relevance: Use the lowest effective dose and duration, reassess whether corticosteroids are necessary, and provide glucose monitoring and sick-day instructions. Review infection, volume status, heart failure, anticoagulant, antiplatelet, and gastrointestinal bleeding risks.
Caveats: The self-controlled design reduces confounding by fixed patient characteristics but cannot fully separate medication effects from the acute condition prompting treatment. Results from one health system may not generalize uniformly.
14. Later vascular disease may explain much of the dementia association after hypertensive pregnancy
What changed: A Korean cohort of approximately 1.37 million women examined dementia after hypertensive disorders of pregnancy over a median follow-up of 21 years.
Why it matters for clinicians: Hypertensive pregnancy was associated with higher dementia risk in baseline-adjusted analyses, but the association attenuated after accounting for subsequent hypertension, diabetes, stroke, and cardiovascular disease. The fully adjusted hazard ratio was 1.15 and was not statistically significant.
Practical clinical relevance: Hypertensive pregnancy should remain a marker for long-term cardiovascular and metabolic surveillance. Blood pressure, lipids, glycemia, smoking, weight, and physical activity deserve continued attention.
Caveats: Dementia remained rare, with only 18 cases among exposed women. Claims-based diagnoses, residual confounding, and limited assessment of dementia subtypes constrain interpretation. The study does not establish a separate indication for dementia screening.
15. Consensus guideline standardizes personalized bacteriophage therapy
What changed: An international consensus group published more than 60 recommendations covering patient selection, infrastructure, quality-controlled phage preparation, clinical administration, monitoring, documentation, and research priorities.
Why it matters for clinicians: Personalized phage treatment is increasingly considered for difficult-to-treat bacterial infections, but clinical pathways and manufacturing standards have varied widely.
Practical clinical relevance: Potential use should occur through specialist infectious-disease, microbiology, pharmacy, regulatory, and source-control teams. Quality assurance must address phage identity, host range, purity, sterility, endotoxin content, resistance, pharmacologic strategy, and outcome documentation.
Caveats: This is consensus guidance, not randomized proof of efficacy. Availability, manufacturing capability, regulation, and permitted access pathways vary by jurisdiction. Phage therapy generally remains adjunctive and should not displace appropriate antibiotics, surgery, drainage, or device management.
Nature Medicine consensus statement
16. Antidepressants differ modestly in short-term QTc effects
What changed: An individual participant data network meta-regression combined 35 double-blind randomized trials involving 8,679 adults. Aggregate cardiovascular outcome analyses included 139 trials and 52,398 participants.
Why it matters for clinicians: Escitalopram increased QTc by an average of 8.7 ms and amitriptyline by 5.3 ms relative to placebo. The analysis did not identify an increase in early major cardiovascular events or non-suicidal death across antidepressants as a group.
Practical clinical relevance: Drug choice should incorporate baseline QTc, age, structural heart disease, electrolyte abnormalities, renal or hepatic impairment, dose, interacting medications, and concurrent QT-prolonging drugs. ECG and electrolyte monitoring remain appropriate for higher-risk patients.
Caveats: Trial follow-up was generally about eight weeks, individual-drug event data were sparse, and trial participants may underrepresent patients with substantial cardiac risk. QTc is a surrogate and does not perfectly predict torsades de pointes.
17. Long-term publication supports etuvetidigene autotemcel for Wiskott-Aldrich syndrome
What changed: Integrated follow-up from two open-label studies and an expanded-access program included 27 recipients of autologous lentiviral gene therapy. The treatment was previously approved by FDA in December 2025; the new development is the peer-reviewed long-term report.
Why it matters for clinicians: Overall survival was 96% at one and five years. Severe infections declined from 2.00 to 0.15 events per person-year, while moderate or severe bleeding decreased from 2.00 to 0.80 events per person-year. Median follow-up was 5.7 years.
Practical clinical relevance: Eligible patients require assessment at a specialized gene-therapy or transplant center, including donor availability, conditioning risk, immune status, infection management, organ function, fertility implications, and long-term surveillance.
Caveats: Evidence came from 27 nonrandomized patients, with outcomes compared partly against pretreatment periods. No insertional oncogenesis was observed, but the cohort is too small to exclude rare or very delayed genotoxicity.
18. NHS-Galleri analysis shows high specificity but limited multi-cancer screening sensitivity
What changed: A prespecified descriptive analysis reported three-round test performance among intervention-arm participants in the 142,250-person NHS-Galleri randomized trial.
Why it matters for clinicians: Positive predictive value declined from 58.0% in round one to 45.8% in round three, while specificity remained approximately 99.5%-99.6%. Cancer signal origin accuracy exceeded 91%. However, overall episode sensitivity ranged from only 26.7% to 37.2%.
Practical clinical relevance: A positive result requires structured diagnostic evaluation, while a negative result cannot exclude cancer. The test should not replace symptom evaluation or guideline-recommended breast, cervical, colorectal, lung, or other screening.
Caveats: These were descriptive secondary performance endpoints. The parent trial did not meet its primary endpoint of reducing stage III or IV cancer incidence. Effects on cancer mortality, overdiagnosis, resource use, and population-level benefit remain unresolved.
19. Albuminuria testing identifies substantial unrecognized CKD in heart failure
What changed: A secondary analysis of FINEARTS-HF evaluated kidney disease among 5,797 patients with symptomatic heart failure and left ventricular ejection fraction of at least 40%.
Why it matters for clinicians: CKD was present in 65.5%, including 40.5% with previously undiagnosed disease. Compared with no CKD, undiagnosed CKD was associated with a 47% higher adjusted rate of cardiovascular death or total heart-failure events.
Practical clinical relevance: Assess both estimated glomerular filtration rate and urine albumin-creatinine ratio in HFmrEF and HFpEF. Albuminuria identified many patients who would have been missed by filtration-based assessment alone. Finerenone benefit appeared consistent across CKD categories.
Caveats: CKD classification incorporated a single urine albumin measurement, and patients with eGFR below 25 mL/min/1.73 m2 were excluded. Clinical outcome associations were observational within the randomized trial and may retain residual confounding.
20. WHO warns that physician aging will intensify global workforce shortages
What changed: WHO released the first report in a planned annual series using National Health Workforce Accounts data. Nearly one-quarter of physicians across 122 countries were older than 55; the proportion approached one-third in high-income countries.
Why it matters for clinicians: WHO projects a global shortage of 11.1 million health workers by 2030, with 67 countries expected to lack enough workers to meet population health needs. Retirement pressure coincides with increasing demand from aging populations.
Practical clinical relevance: Health systems should strengthen succession planning, training capacity, retention, occupational health, team-based care, task sharing, and geographic workforce distribution. Clinical leaders should anticipate effects on access, continuity, supervision, and specialty coverage.
Caveats: National data completeness, definitions, occupational classifications, and reporting years vary. These projections describe system-level capacity and do not predict staffing conditions in every institution or specialty.
Week in perspective
This week’s most immediate practice changes arise from four FDA approvals and the neonatal CPAP recall. The oncology approvals reinforce the importance of molecular testing for ESR1 mutations and FGFR2 alterations, while belzutifan plus lenvatinib offers an additional post-immunotherapy renal cancer option. Each approval also illustrates the need to separate improvements in response or progression-free survival from proven gains in overall survival.
Several reports support more systematic risk detection. Hepatitis A prevention should be addressed before travel to Cuba, and both eGFR and albuminuria testing are needed to detect the large burden of unrecognized CKD in heart failure. The kidney-transplant analysis similarly suggests that clinical referral alone may be insufficient when insurance design and administrative barriers influence access.
The randomized evidence produced important narrowing findings. Transvaginal drainage did not establish noninferiority to laparoscopy for tubo-ovarian abscess, and therapeutic anticoagulation did not significantly improve outcomes in the small hospitalized COVID-19 trial. IV iron improved hematologic outcomes during pregnancy, but evidence for better obstetric outcomes remains limited.
Finally, the phage-therapy consensus and long-term Wiskott-Aldrich gene-therapy results illustrate two different stages of therapeutic development. Phage therapy is moving toward standardized clinical pathways despite limited comparative efficacy evidence, while etuvetidigene autotemcel now has encouraging multi-year follow-up but remains supported by a very small, nonrandomized population. In both settings, specialized infrastructure, prospective monitoring, and transparent outcome reporting remain essential.
Recent Articles
Integrative Perspectives on Cognition, Emotion, and Digital Behavior
Sleep-related:
Longevity/Nutrition & Diet:
Philosophical / Happiness / Social:
Other:
Modern Mind Unveiled
Developed under the direction of David McAuley, Pharm.D., this collection explores what it means to think, feel, and connect in the modern world. Drawing upon decades of clinical experience and digital innovation, Dr. McAuley and the GlobalRPh initiative translate complex scientific ideas into clear, usable insights for clinicians, educators, and students.
The series investigates essential themes–cognitive bias, emotional regulation, digital attention, and meaning-making—revealing how the modern mind adapts to information overload, uncertainty, and constant stimulation.
At its core, the project reflects GlobalRPh’s commitment to advancing evidence-based medical education and clinical decision support. Yet it also moves beyond pharmacotherapy, examining the psychological and behavioral dimensions that shape how healthcare professionals think, learn, and lead.
Through a synthesis of empirical research and philosophical reflection, Modern Mind Unveiled deepens our understanding of both the strengths and vulnerabilities of the human mind. It invites readers to see medicine not merely as a science of intervention, but as a discipline of perception, empathy, and awareness–an approach essential for thoughtful practice in the 21st century.
The Six Core Themes
I. Human Behavior and Cognitive Patterns
Examining the often-unconscious mechanisms that guide human choice-how we navigate uncertainty, balance logic with intuition, and adapt through seemingly irrational behavior.
II. Emotion, Relationships, and Social Dynamics
Investigating the structure of empathy, the psychology of belonging, and the influence of abundance and selectivity on modern social connection.
III. Technology, Media, and the Digital Mind
Analyzing how digital environments reshape cognition, attention, and identity- exploring ideas such as gamification, information overload, and cognitive “nutrition” in online spaces.
IV. Cognitive Bias, Memory, and Decision Architecture
Exploring how memory, prediction, and self-awareness interact in decision-making, and how external systems increasingly serve as extensions of thought.
V. Habits, Health, and Psychological Resilience
Understanding how habits sustain or erode well-being-considering anhedonia, creative rest, and the restoration of mental balance in demanding professional and personal contexts.
VI. Philosophy, Meaning, and the Self
Reflecting on continuity of identity, the pursuit of coherence, and the construction of meaning amid existential and informational noise.
Keywords
Cognitive Science • Behavioral Psychology • Digital Media • Emotional Regulation • Attention • Decision-Making • Empathy • Memory • Bias • Mental Health • Technology and Identity • Human Behavior • Meaning-Making • Social Connection • Modern Mind
Video Section
